Form 6-K/A GLAXOSMITHKLINE PLC For: Jan 15
FORM 6-K/A
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
the Securities Exchange Act of 1934
�
�
�
For period ending�January 2015
�
GlaxoSmithKline plc
(Name of registrant)(
�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(
�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(
�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(
�
�
Yes����� No x
--
�
This announcement replaces the original announcement released on 5 January 2015.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the 'Company').
On 31 December 2014, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2014; calculated using an average price of �13.84 per Ordinary Share and $42.91 per ADS:
�
Non-Executive Director
|
Ordinary Shares
|
No. of ADSs
|
Sir Christopher Gent
|
6,385.452
|
� |
Prof Sir Roy Anderson
|
1,003.260
|
� |
Dr Stephanie Burns
|
� |
886.521
|
Stacey Cartwright
|
256.043
|
� |
Lynn Elsenhans
|
� |
308.422
|
Judy Lewent
|
� |
208.857
|
Sir Deryck Maughan
|
� |
2,255.597
|
Dr Daniel Podolsky
|
� |
1,613.970
|
Tom de Swaan
|
1,389.497
|
� |
Jing Ulrich
|
� |
98.139
|
Hans Wijers
|
76.661
|
� |
The Company and the Non-Executive Directors were informed of these allocations on 5 January 2015.
This notification relates to transactions notified in accordance with�Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
�
15 January 2015
�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(
�
�
GlaxoSmithKline plc
(Registrant)(
Date:�January�15,�2015�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) call put ratio 12 calls to 1 put with focus on April weekly (26) 41 calls
- Start of Day Message
- Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!